Advances in the Management of Cystic Fibrosis: A Closer
Look at the Roles of CFTR Modulation Therapy

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 15, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Vertex Pharmaceuticals

According to the Cystic Fibrosis (CF) Foundation, about 30,000 people are currently living with cystic fibrosis, and approximately 1,000 new cases of CF are diagnosed each year. There is no cure for cystic fibrosis, but recent treatment breakthroughs have the ability to provide a greater quality of life and improved outcomes for patients with CF. CF is an autosomal recessive disorder, caused by the presence of mutations in both copies of the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR). Fortunately for about half of CF patients, a new treatment is available for those who have two copies of the F508del mutation in their CFTR gene. This new CFTR modulation therapeutic focuses on counteracting the damage caused by the disease, enabling patients to breathe more easily and stay out of the hospital, improving outcomes and quality of life. This option is a major breakthrough in CF management, because it is the first therapy that specifically targets an important genetic mutation.

Upon Completion of this activity, participants will be able to:

  • Assess newly approved and emerging CFTR-targeted treatment strategies according to their mechanism of action, efficacy, and safety

  • Examine the role of CFTR modulation therapy in the treatment and management of cystic fibrosis

  • Discuss the importance of genetic testing in suspected adult-onset CF

  • Analyze optimal strategies to manage and monitor CFTR modulator-related adverse events in cystic fibrosis patients

  • Explore strategies to employ a multidisciplinary approach to management of the CF patient, and communicate effectively with patients and their families about the role of genetic analysis

Faculty: Susanna A. McColley, MD
Associate Chief Research Officer
Stanley Manne Children’s Research Institute
Associate Clinical Director for Child Health, Northwestern University Clinical and Translational Sciences Institute
Professor of Pediatrics, Northwestern University Feinberg School of Medicine
Associate Director, Cystic Fibrosis Center
Division of Pulmonary Medicine


Dr. McColley serves as a consultant to AbbVie and Vertex Pharmaceuticals. Her presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Vertex Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue